Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence

References

• Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the national Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185-9
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel III. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [final report]. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Eng J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007;23:553-63
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Cziraky MJ, Stanek EJ, et al. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?. Clin Ther 2007;29:196-209
   PubMed Web of Science ®Google Scholar
• Windler E, Schoffauer M, Zyriax B-C. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diabetes Vasc Dis Res 2007;4:136-42
   PubMedGoogle Scholar
• Quimbo RA, Simko RJ, Cziraky MJ, et al. Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US. J Med Econ 2008;11:449-70
   PubMedGoogle Scholar
• Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
   PubMed Web of Science ®Google Scholar
• Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2007;167:1798-803
   PubMed Web of Science ®Google Scholar
• Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:SP11-19
   PubMed Web of Science ®Google Scholar
• Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 2004;19:638-45
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279:1458-62
   Google Scholar
• Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61
   PubMed Web of Science ®Google Scholar
• Schultz JS, O’Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12
   PubMed Web of Science ®Google Scholar
• Sung JCY, Nichol MB, Venturini F, et al. factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:1421-30
   PubMed Web of Science ®Google Scholar
• Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007;29:2748-57
   PubMed Web of Science ®Google Scholar
• Batal HA, Krantz MJ, Dale RA, et al. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 2007;7:175
   PubMed Web of Science ®Google Scholar
• Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005;23:13-25
   PubMed Web of Science ®Google Scholar
• Patel BV, Remigio-Baker RA, Thiebauld P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61
   PubMed Web of Science ®Google Scholar
• Legorreta A, Yu A, Chernicoff H, et al. Adherence to combined lamivudine zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care 2005;17:938-48
   PubMed Web of Science ®Google Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-14
   PubMed Web of Science ®Google Scholar
• Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Becker DM, Allen JK. Improving compliance in your dyslipidemia patient: an evidence-based approach. J Am Acad Nurse Pract 2001;13:200-7
   PubMedGoogle Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-8
   PubMed Web of Science ®Google Scholar
• Murray MD, Kroenke K. Polypharmacy and medication adherence: small steps on a long road. J Gen Intern Med 2001;16:137-9
   PubMed Web of Science ®Google Scholar
• Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q 2008;31:40-5
   PubMedGoogle Scholar
• Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2:485-501
   PubMedGoogle Scholar
• LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form niacin extended-release/lovastatin compared with statin alone or in combination with niacin extended-release. Ann Pharmacother 2006;40:1274-9
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veteran Affairs. Am J Med 2007;120:26-32
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29
   PubMed Web of Science ®Google Scholar
• Vinker S, Shani M, Baevsky T, et al. Adherence with statins over 8 years in a usual care setting. Am J Manag Care 2008;14:388-92
   PubMed Web of Science ®Google Scholar
• Natarajan N, Putnam RW, Yip AM, et al. Family practice patients’ adherence to statin medications. Can Fam Physician 2007;53:2144-5
   PubMedGoogle Scholar
• Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005;22:163-71
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
   PubMed Web of Science ®Google Scholar
• Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119:390-7
   PubMed Web of Science ®Google Scholar
• Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Stuart BC, Simoni-Wastila L, Zhao L, et al. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care 2009;32:647-9
   PubMed Web of Science ®Google Scholar
• Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-51
   PubMed Web of Science ®Google Scholar
• Meyers CD, Carr MC, Park S, et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003;139:996-1002
   PubMed Web of Science ®Google Scholar